Highlights
- Ryoncil® revenue rose 60% quarter-on-quarter to USD 35.1 million
- Mesoblast secured a new USD 125 million five-year financing facility
- Shares creates a fresh 52-week high of AUD 3.31 on Friday
Mesoblast Ltd (ASX:MSB) surged to fresh highs on Friday (9 January 2026), touching its 52-week peak of AUD 3.31 during the trading session after releasing an update that showed a sharp increase in quarterly revenue from its flagship therapy, Ryoncil®. The biotech company’s share price climbed to around AUD 3.25 at the time of writing on 9 January 2026, marking a gain of more than 10% on the day and extending its January rally to nearly 19%.
Ryoncil Sales Deliver Quarterly Lift
Mesoblast reported gross revenue of USD 35.1 million from Ryoncil® sales for the quarter ended 31 December 2025. This marked a 60% increase compared with the September 2025 quarter, driven by continued uptake of the therapy in the United States.
Ryoncil® (remestemcel-L-rknd) holds the distinction of being the first mesenchymal stromal cell (MSC) therapy approved by the U.S. Food and Drug Administration for any indication. It is currently approved for children under the age of 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
Expansion Plans
Beyond its existing pediatric indication, Ryoncil® is set to be evaluated in a pivotal clinical trial as part of a second-line treatment regimen for adults with SR-aGvHD. This adult market is estimated to be approximately three times larger than the pediatric segment, creating a pathway for broader commercial reach.
The company is also advancing development programs for other inflammatory and chronic conditions, including biologic-resistant inflammatory bowel disease, heart failure, and chronic low back pain through its remestemcel-L and rexlemestrocel-L platforms.
New Financing Reshapes Capital Structure
Mesoblast also announced a new USD 125 million five-year interest-only facility with its largest shareholder. The financing enabled the company to fully repay its prior senior secured loan and partially repay its subordinated royalty facility, which is expected to be fully cleared by mid-calendar year 2026.
The facility features lower overall costs, no early repayment penalties, no exit fees, and does not place restrictions on future unsecured debt or licensing arrangements. Importantly, it does not encumber Mesoblast’s key assets or intellectual property portfolio.
Market Reaction and Share Performance
Following the update, Mesoblast shares moved sharply higher, touching 52-week high of AUD 3.31. At around AUD 3.25, the stock has added nearly 19% so far in January.






Please wait processing your request...